bioRxivBiochemistry
Mapping of a N-terminal α-helix domain required for human PINK1 stabilisation, Serine228 autophosphorylation and activation in cells
P. Kakade, H. Ojha, O. Raimi, A. Shaw, A. Waddell, J. Ault, S. Burel, K. Brockmann, A. Kumar, M. Ahanger, E. Krysztofinska, T. Macartney, R. Bayliss, J. C. Fitzgerald, M. Muqit
Abstract
Human autosomal recessive mutations in the PINK1 gene are causal for Parkinsons disease (PD). PINK1 encodes a mitochondrial localised protein kinase that is a master-regulator of mitochondrial quality control pathways. Structural studies to date have elaborated the mechanism of how mutations located within the kinase domain disrupt PINK1 function, however, the molecular mechanism of PINK1 mutations located upstream and downstream of the kinase domain are unknown. We have employed mutagenesis studies of human PINK1 in cells to define the minimal region of PINK1, required for optimal ubiquitin phosphorylation, beginning at residue Ile111. Bioinformatic analysis of the region spanning Ile111 to the kinase domain and inspection of the AlphaFold human PINK1 structure model predicts a conserved N-terminal -helical domain extension (NTE domain) within this region corroborated by hydrogen/deuterium exchange mass spectrometry (HDX-MS) of recombinant insect PINK1 protein. The AlphaFold structure also predicts the NTE domain forms an intramolecular interaction with the C-terminal extension (CTE). Cell-based analysis of human PINK1 reveals that PD-associated mutations (e.g. Q126P), located within the NTE:CTE interface, markedly inhibit stabilization of PINK1; autophosphorylation at Serine228 (Ser228); and Ubiquitin Serine65 (Ser65) phosphorylation. Furthermore, we provide evidence that NTE domain mutants do not affect intrinsic catalytic kinase activity but do disrupt PINK1 stabilisation at the mitochondrial Translocase of outer membrane (TOM) complex. The clinical relevance of our findings is supported by the demonstration of defective stabilization and activation of endogenous PINK1 in human fibroblasts of a patient with early-onset PD due to homozygous PINK1 Q126P mutations. Overall, we define a functional role of the NTE:CTE interface towards PINK1 stabilisation and activation and show that loss of NTE:CTE interactions is a major mechanism of PINK1-associated mutations linked to PD.
- organism: human
- assay: proteomics
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure of PINK1 reveals autophosphorylation dimer and provides insights into binding to the TOM complex
S. Rasool, S. Veyron, … J.-F. Trempe·bioRxiv·Aug 5, 2021
- Regulation of Human PINK1 ubiquitin kinase by Serine167, Serine228 and Cysteine412 phosphorylation
A. Waddell, H. Ojha, … M. Muqit·bioRxiv·Mar 31, 2023
- Evolutionary analysis of PINK1 reveals key roles of the N- and C-terminal extensions and TOM20 in folding its kinase domain
Tara Shomali, Simon Veyron, Jean‐François Trempe·bioRxiv·Sep 9, 2026
- PINK1-G411S mutant increases kinase stability and enhances mitochondrial-linked functions
Filipa Barroso Gonçalves, Francisco J. Enguita, Vanessa A. Morais·bioRxiv·Jun 28, 2024
- An in-silico approach to study the molecular interaction of the PINK1 kinase domain with Parkin Ubl domain
Sima Biswas, Sreekanya Roy, Angshuman Bagchi·bioRxiv·May 2, 2023
- Identification and structural characterization of small-molecule inhibitors of PINK1
S. Rasool, T. Shomali, … J.-F. Trempe·bioRxiv·Oct 2, 2023